ClinicalTrials.gg
RecruitingNCT06554509Updated Apr 29, 2026

Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis

A Phase 2/3 interventional study of SHR-1819 Injection and SHR-1819 Injection Placebo in Prurigo Nodularis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
423
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.

02

Conditions studied

  • Prurigo Nodularis

Browse trials for

03

In context

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

This study's planned enrollment of 423 is above the median of 135 across 31 interventional studies indexed under Prurigo.

Browse Prurigo studies →

Lead sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily sign forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol.
  2. The age was ≥18 at the time of signing the informed consent and gender is unlimited.
  3. Has prurigo nodularis at screening.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Screening for people with a history of heavy alcohol consumption or substance abuse in the 6 months prior to screening.
  3. Has an active skin disease or skin complications due to other diseases that may affect the evaluation of PN.
  4. PN secondary to medical conditions such as neurological or psychiatric disorders.
  5. Diagnosis of moderate to severe AD during the screening/lead-in period or prior to randomization.
  6. History of diseases (e.g., circulatory system abnormalities, endocrine system abnormalities, neurological disorders, hematologic disorders, immune system disorders, psychiatric disorders, and metabolic instability) that the researcher believes that participation in the study poses a risk to the safety of the subject or that the disease/illness worsens during the study period will affect the effectiveness or safety analysis.
  7. Phase II: Treated with biologics targeting IL-4Rα, or participated in previous clinical studies of biologics targeting IL-4Rα, including SHR-1819 injection. Phase III: Subjects who have previously received anti-IL-4Rα biologics for any indication including atopic dermatitis (AD), asthma, sinusitis, etc., and were judged by the investigator to have an inadequate response or intolerance (e.g., experienced drug-related adverse reactions requiring treatment discontinuation) must be excluded even if the requirement is met.
  8. Subjects with prior to screening (except for squamous cell carcinoma of the skin, basal cell carcinoma, or carcinoma in situ of the cervix that are completely resected and have no evidence of recurrence).
  9. Major surgeries are planned for the duration of the study.
  10. Other conditions that, in the opinion of the investigator, are not suitable for participation in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
423 participants (estimated)

Study arms

  • Experimental
    SHR-1819 Injection Group

    SHR-1819 injection with different doses.

    Drug: SHR-1819 Injection

  • Placebo comparator
    SHR-1819 Injection Placebo Group

    SHR-1819 injection placebo.

    Drug: SHR-1819 Injection Placebo

Interventions

  • SHR-1819 injection.

  • DrugSHR-1819 Injection Placebo

    SHR-1819 injection placebo.

06

What researchers measure

Primary outcomes

  1. Phase II: Proportion of subjects with a ≥ 4-point reduction from baseline in the weekly mean of the Most Intense Pruritus Numeric Rating Scale (WI-NRS) at Week 16

    Participants were asked daily to rate the intensity of their worst pruritus (itch) over the past 24 hours, using a 11-point scale ranging from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicated more severity.

    Time frame: Up to 16 weeks.

  2. Phase III: Proportion of subjects with a ≥ 4-point reduction from baseline in the weekly mean of the Most Intense Pruritus Numeric Rating Scale (WI-NRS) at Week 24

    Participants were asked daily to rate the intensity of their worst pruritus (itch) over the past 24 hours, using a 11-point scale ranging from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicated more severity.

    Time frame: Up to 24 weeks.

Secondary outcomes

  1. Phase II: Weekly mean change from baseline and percentage change in weeks 2, 4, 8, 12, and 16 of WI-NRS

    Participants were asked daily to rate the intensity of their worst pruritus (itch) over the past 24 hours, using a 11-point scale ranging from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicated more severity.

    Time frame: Up to 16 weeks.

  2. Phase II: Proportion of subjects with IGA CNPG-S score of 0/1 at weeks 4, 8, 12 and 16

    It consists of a 5-point scale ranging from 0 to 4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. Higher scores indicate severe PN.

    Time frame: Up to 16 weeks.

  3. Phase II: Change from baseline in Dermatology Life Quality Index (DLQI) score at weeks 4, 8, 12, 16

    It comprises of set of 10 questions. Responses to each question were assessed on a 4-point Likert scale ranged from 0 (not at all) to 3 (very much). Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.

    Time frame: Up to 16 weeks.

  4. Phase III: Proportion of subjects with an IGA CNPG-S score of 0/1 at Week 24

    It consists of a 5-point scale ranging from 0 to 4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. Higher scores indicate severe PN.

    Time frame: Up to 24 weeks.

  5. Phase III: Proportion of subjects with IGA CNPG-S score of 0/1 at every study visit

    It consists of a 5-point scale ranging from 0 to 4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. Higher scores indicate severe PN.

    Time frame: Up to 52 weeks.

  6. Phase III: Change from baseline in Dermatology Life Quality Index (DLQI) score at every study visit

    It comprises of set of 10 questions. Responses to each question were assessed on a 4-point Likert scale ranged from 0 (not at all) to 3 (very much). Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.

    Time frame: Up to 52 weeks.

  7. Phase II/III: The concentration of SHR-1819 in serum (AUC)

    The concentration of SHR-1819 in plasma will be determined.

    Time frame: From the beginning of administration to the 24/60th week.

  8. Phase II/III: Changes in the level of IgE in the serum

    Changes in the level of biomarkers in serum.

    Time frame: From the beginning of administration to the 24/60th week.

  9. Phase II/III: Immunogenic endpoint - evaluate the incidence of ADA positivity for SHR-1819

    Incidence of immunogenicity in the body.

    Time frame: From the beginning of administration to the 24/60th week.

07

Study locations

1 of 1 sites recruiting
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100032, China
    Recruiting
    • Jianzhong Zhang · ContactRmzjz@126.com · +86-18001315877
    • Jianzhong Zhang · Principal investigator
    • Cheng Zhou · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Oct 2028, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 15, 2024
StartActual
Sep 19, 2024
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06554509
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Sep 19, 2024
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Huiliu Wang
Contact
huiliu.wang.hw330@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drotokibart

Start the discussion